The head of government, Pedro Sánchez, met with the vice president this Monday to discuss a new chapter in Spain’s pharmaceutical landscape. Moderna, a leader in messenger RNA technology, announced a major investment in Spain that surpasses 500 million euros. The development signals a strong push to position the country as a hub for advanced biotechnologies on the European continent, with Spain set to benefit from increased research capacity and high-tech manufacturing capabilities.
In a subsequent statement from La Moncloa, Moderna disclosed plans to establish a quality testing laboratory on Spanish soil dedicated to vaccines based on messenger RNA. This facility will support rigorous testing and quality control for RNA-based vaccines and therapies, reinforcing Spain’s role in ensuring high standards for medical innovation across Europe.
The meeting, attended by Health Minister Carolina Darias and Economic Affairs Secretary General Manuel de la Rocha, focused on Moderna’s commitment to integrating RNA technology within Spain and Europe. Representatives from Moderna including Nicholar Chornet, the vice president of production, and Juan Carlos Gil, the general manager for Spain and Portugal, were present to discuss implementation timelines, regulatory expectations, and collaboration with local stakeholders.
Moncloa officials highlighted Moderna’s readiness to receive government support as Spain aims to become a benchmark for pharmaceutical innovation. Current projects include a messenger RNA vaccine manufacturing facility in Granada and an additional site in San Sebastián de los Reyes, Madrid, developed in partnership with Rovi. These facilities are expected to enhance Spain’s capacity to produce cutting-edge vaccines and accelerate access to novel therapies for European populations.
Sánchez emphasized the government’s sustained backing for the pharmaceutical sector and research and development activities. The administration has maintained a robust fiscal stance to strengthen science and innovation, with the budget for the Ministry of Science and Innovation expanding significantly in recent years to fuel transformative projects and scientific programs. The government views the science and technology sectors as central to economic resilience and long-term growth, particularly in the context of recovery and transformation efforts.
The strategic focus on health and innovation aligns with broader national plans that aim to mobilize substantial public and private investment. By prioritizing vaccine manufacturing, research facilities, and regulatory readiness, Spain seeks to attract international partners, accelerate clinical development, and improve public health outcomes across Europe. The partnership with Moderna reflects a commitment to advancing next-generation biologics and strengthening the regional ecosystem that supports pharmaceutical innovation, supply security, and scientific talent development.